123 related articles for article (PubMed ID: 30785571)
21. Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.
McCaffrey R; Bahtiyar M; Kohorn EI; Chambers JT; Schwartz PE; Chambers SK
Int J Gynecol Cancer; 2011 Apr; 21(3):535-44. PubMed ID: 21436702
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix.
Iwasaka T; Fukuda K; Hara K; Yokoyama M; Nakao Y; Uchiyama M; Sugimori H
Gynecol Oncol; 1998 Aug; 70(2):236-40. PubMed ID: 9740697
[TBL] [Abstract][Full Text] [Related]
23. A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin.
Takekuma M; Hirashima Y; Takahashi N; Yamamichi G; Furukawa N; Yamada Y; Takakuwa R; Ito I
Anticancer Drugs; 2006 Jul; 17(6):715-8. PubMed ID: 16917218
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.
Choi CH; Song SY; Choi JJ; Park YA; Kang H; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
BMC Cancer; 2008 Oct; 8():295. PubMed ID: 18847499
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.
Eralp Y; Saip P; Sakar B; Tas F; Aydiner A; Topuz E
Eur J Gynaecol Oncol; 2003; 24(3-4):323-6. PubMed ID: 12807249
[TBL] [Abstract][Full Text] [Related]
26. Texture analysis versus conventional MRI prognostic factors in predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced cancer of the uterine cervix.
Ciolina M; Vinci V; Villani L; Gigli S; Saldari M; Panici PB; Perniola G; Laghi A; Catalano C; Manganaro L
Radiol Med; 2019 Oct; 124(10):955-964. PubMed ID: 31254220
[TBL] [Abstract][Full Text] [Related]
27. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy.
Kastritis E; Bamias A; Efstathiou E; Gika D; Bozas G; Zorzou P; Sarris K; Papadimitriou C; Dimopoulos MA
Gynecol Oncol; 2005 Nov; 99(2):376-82. PubMed ID: 16051322
[TBL] [Abstract][Full Text] [Related]
28. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K
Gynecol Oncol; 2006 Nov; 103(2):618-22. PubMed ID: 16777200
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of neoadjuvant chemotherapy for locally advanced cervical cancinoma].
Cheng XD; Lü WG; Ye F; Chen HZ; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):95-8. PubMed ID: 16640856
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (>/=4 cm) stage IB and IIA cervical carcinoma.
Huang HJ; Chang TC; Hong JH; Tseng CJ; Chou HH; Huang KG; Lai CH
Int J Gynecol Cancer; 2003; 13(2):204-11. PubMed ID: 12657125
[TBL] [Abstract][Full Text] [Related]
31. Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma: II. Its impact on clinical response and subsequent surgery.
Motoyama S; Takeuchi S; Hamana S; Ku Y; Miyahara Y; Tateiwa Y; Yoshida S; Maruo T
Am J Clin Oncol; 2001 Jun; 24(3):247-50. PubMed ID: 11404494
[TBL] [Abstract][Full Text] [Related]
32. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
33. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
34. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Costa S; Terzano P; Bovicelli A; Martoni A; Angelelli B; Santini D; Ceccarelli C; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
Gynecol Oncol; 2001 Jan; 80(1):67-73. PubMed ID: 11136572
[TBL] [Abstract][Full Text] [Related]
35. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
[TBL] [Abstract][Full Text] [Related]
36. Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
Marnitz S; Köhler C; Roth C; Füller J; Bischoff A; Wendt T; Schneider A; Budach V
Strahlenther Onkol; 2007 Sep; 183(9):473-8. PubMed ID: 17762920
[TBL] [Abstract][Full Text] [Related]
37. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.
Chen JL; Huang CY; Huang YS; Chen RJ; Wang CW; Chen YH; Cheng JC; Cheng AL; Kuo SH
Acta Obstet Gynecol Scand; 2014 Jul; 93(7):661-8. PubMed ID: 24666257
[TBL] [Abstract][Full Text] [Related]
38. Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB.
Minig L; Colombo N; Zanagnolo V; Landoni F; Bocciolone L; Cárdenas-Rebollo JM; Iodice S; Maggioni A
Int J Gynecol Cancer; 2013 Nov; 23(9):1647-54. PubMed ID: 24100590
[TBL] [Abstract][Full Text] [Related]
39. [Antitumor effects and clinical problems of transcatheter intraarterial infusion for uterine cervical cancer].
Fujiwara K
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1236-40. PubMed ID: 16969017
[TBL] [Abstract][Full Text] [Related]
40. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
